Antiinfective medicine sales in South Korea were valued at 2.59 billion USD in 2023. From 2024 onwards, the sales are forecasted, starting at 2.62 billion USD in 2024 and gradually increasing to 2.74 billion USD by 2028. This suggests a steady year-on-year growth of approximately 1.15% to 1.14% annually. The last two years saw a minor increase from 2.59 billion USD to 2.62 billion USD, approximately 1.16%. The compound annual growth rate (CAGR) over the forecasted period (2024-2028) is also consistent at around 1.14% per year.
Future trends to watch for include the emergence of antibiotic resistance, advancements in biotechnology, and government policies that could impact the production and sale of antiinfective medicines. Additionally, investments in R&D for new antiinfective drugs and potential changes in healthcare funding may significantly influence market dynamics.
